Neuropsychiatric biotech raises $20M for PhII program

With mid-stage data on its lead drug for tardive dyskinesia--a chronic movement disorder--expected in early 2015, Waltham, MA-based Synchroneuron says it's raised $20 million from its sole investor: Morningside Technology. The biotech is also planning to launch studies for SNC-102 in Tourette syndrome and post-traumatic stress syndrome. Accellient seeded Synchroneuron up to its $6 million Series A from Morningside. Release

Suggested Articles

CNS Pharma says berubicin is the first anthracycline drug to cross the blood-brain barrier and could transform treatment of the highly invasive brain tumor.

Grid Therapeutics is planning to start trials of its lead cancer immunotherapy GT103 next year after raising $5 million in second-round financing.

The IPO comes as the Flagship startup prepares to test its lead inflammatory disease and anticancer microbial strains in humans.